Arcutis Pharmaceuticals
900 Island Drive, Suite 210
Redwood City
California
94065
United States
57 articles about Arcutis Pharmaceuticals
-
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
3/10/2024
Arcutis Biotherapeutics, Inc., presented in a late-breaking clinical trial session at the American Academy of Dermatology annual meeting new data from its INTEGUMENT-PED pivotal Phase 3 study of investigational roflumilast cream 0.05% in children 2 to 5 years of age with mild to moderate atopic dermatitis.
-
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
3/9/2024
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis.
-
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
2/29/2024
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference.
-
Arcutis Announces Proposed Public Offering - February 28, 2024
2/28/2024
Arcutis Biotherapeutics, Inc. announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
-
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/27/2024
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported financial results for the quarter and year ended December 31, 2023, and provided a business update.
-
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
1/14/2024
Arcutis Biotherapeutics, Inc. announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times more likely to achieve IGA Success with ZORYVE® topical foam, 0.3%, compared to vehicle i.
-
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
1/14/2024
Arcutis Biotherapeutics, Inc. announced new individual patient response data showing the vast majority of individuals treated with investigational roflumilast cream 0.15% had a measurable improvement in Eczema Area and Severity Index in 4 weeks.
-
This week, the FDA could approve the first CRISPR-edited therapy in the U.S., while two other companies await decisions on topical drugs.
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2023
11/2/2023
Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 52,500 restricted stock units of Arcutis’ common stock to eight newly hired employees.
-
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
10/20/2023
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new individual patient response data showing nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in Psoriasis Area and Severity Index (PASI).
-
Arcutis Announces Proposed Public Offering - October 19, 2023
10/19/2023
Arcutis Biotherapeutics, Inc. announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
-
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
10/13/2023
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis.
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2023
10/5/2023
Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of inducement awards to L. Todd Edwards, its new Chief Commercial Officer.
-
Arcutis to Present at Upcoming September 2023 Investor Conference
9/5/2023
Arcutis Biotherapeutics, Inc., an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis management will participate in an upcoming investor conference.
-
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
8/29/2023
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of The Cream That Can, the first commercial direct-to-consumer ad for ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents.
-
Arcutis Appoints Interim Chief Financial Officer (CFO)Former and First Arcutis CFO, John Smither, Appointed Interim
8/18/2023
Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced that John W. Smither, who served as Arcutis’ first Chief Financial Officer from 2019 to 2021, has been appointed interim CFO effective August 31.
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 04, 2023
8/4/2023
Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 38,500 restricted stock units of Arcutis’ common stock to five newly hired employees.
-
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
7/17/2023
Arcutis Biotherapeutics, Inc. announced that ZORYVE® cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5.
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 05, 2023
7/5/2023
Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 60,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to seven newly hired employees.
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 05, 2023
6/5/2023
Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 58,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to seven newly hired employees.